147 related articles for article (PubMed ID: 15956071)
1. Intravenous iron-gluconate during haemodialysis modifies plasma beta2-microglobulin properties and levels.
Michelis R; Sela S; Kristal B
Nephrol Dial Transplant; 2005 Sep; 20(9):1963-9. PubMed ID: 15956071
[TBL] [Abstract][Full Text] [Related]
2. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
[TBL] [Abstract][Full Text] [Related]
3. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
[TBL] [Abstract][Full Text] [Related]
4. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
Traut M; Haufe CC; Eismann U; Deppisch RM; Stein G; Wolf G
Blood Purif; 2007; 25(5-6):432-40. PubMed ID: 17957097
[TBL] [Abstract][Full Text] [Related]
5. [LEVEL AND OXIDATION OF BETA 2-MICROGLOBULIN IN HEMODIALYSIS PATIENTS TREATED WITH INTRAVENOUS IRON DURING DIALYSIS WITH HIGH-FLUX COMPARED TO LOW-FLUX DIALYZERS].
Michelis R; Sela S; Lanzmann A; Tanchilevski O; Shurtz-Swirski R; Kristal B
Harefuah; 2017 May; 156(5):289-293. PubMed ID: 28551910
[TBL] [Abstract][Full Text] [Related]
6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of beta2-microglobulin and phosphate during hemodialysis: effects of treatment frequency and duration.
Leypoldt JK
Semin Dial; 2005; 18(5):401-8. PubMed ID: 16191181
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
[TBL] [Abstract][Full Text] [Related]
9. Salivary beta2-microglobulin analysis in chronic kidney disease and hemodialyzed patients.
Michelis R; Sela S; Ben-Zvi I; Nagler RM
Blood Purif; 2007; 25(5-6):505-9. PubMed ID: 18187941
[TBL] [Abstract][Full Text] [Related]
10. Reduction in beta2-microglobulin with super-flux versus high-flux dialysis membranes: results of a 6-week, randomized, double-blind, crossover trial.
Pellicano R; Polkinghorne KR; Kerr PG
Am J Kidney Dis; 2008 Jul; 52(1):93-101. PubMed ID: 18423807
[TBL] [Abstract][Full Text] [Related]
11. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
12. Effect of Membrane Permeability on Cardiovascular Risk Factors and β2m Plasma Levels in Patients on Long-Term Haemodialysis: A Randomised Crossover Trial.
Chazot C; Kirchgessner J; Pham J; Vo-Van C; Lorriaux C; Hurot JM; Zaoui E; Grassmann A; Jean G; Marcelli D
Nephron; 2015; 129(4):269-75. PubMed ID: 25825336
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study.
Pai AB; Norenberg J; Boyd A; Raj D; Chan LN
Clin Ther; 2007 Dec; 29(12):2699-705. PubMed ID: 18201586
[TBL] [Abstract][Full Text] [Related]
14. Effects of intravenous iron on mononuclear cells during the haemodialysis session.
Martin-Malo A; Merino A; Carracedo J; Alvarez-Lara MA; Ojeda R; Soriano S; Crespo R; Ramirez R; Aljama P
Nephrol Dial Transplant; 2012 Jun; 27(6):2465-71. PubMed ID: 22207322
[TBL] [Abstract][Full Text] [Related]
15. The effect of on-line high-flux hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized controlled trial.
Santoro A; Mancini E; Bolzani R; Boggi R; Cagnoli L; Francioso A; Fusaroli M; Piazza V; Rapanà R; Strippoli GF
Am J Kidney Dis; 2008 Sep; 52(3):507-18. PubMed ID: 18617304
[TBL] [Abstract][Full Text] [Related]
16. Intravenous iron attenuates postvaccination anti-HBsAg titres after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy.
Liu JH; Liu YL; Lin HH; Yang YF; Kuo HL; Lin PW; Huang CC
Int J Clin Pract; 2009 Mar; 63(3):387-93. PubMed ID: 18410348
[TBL] [Abstract][Full Text] [Related]
17. Uraemic itching: do polymethylmethacrylate dialysis membranes play a role?
Aucella F; Vigilante M; Gesuete A; Maruccio G; Specchio A; Gesualdo L
Nephrol Dial Transplant; 2007 Jul; 22 Suppl 5():v8-12. PubMed ID: 17586845
[TBL] [Abstract][Full Text] [Related]
18. Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients.
Guz G; Glorieux GL; De Smet R; Waterloos MA; Vanholder RC; Dhondt AW
Nephrol Dial Transplant; 2006 Oct; 21(10):2834-40. PubMed ID: 16762960
[TBL] [Abstract][Full Text] [Related]
19. Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex.
Winkelmayer WC; Goldstein BA; Mitani AA; Ding VY; Airy M; Mandayam S; Chang TI; Brookhart MA; Fishbane S
Am J Kidney Dis; 2017 Jun; 69(6):771-779. PubMed ID: 28063734
[TBL] [Abstract][Full Text] [Related]
20. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]